SNM 2011: Find out How to Meet the PET Deadline at SNM Meeting | SNM 2011
LinkedIn Login

Connect healthcare products, companies and hospitals with your LinkedIn network.

Facebook Login

Interact with your Facebook network around healthcare products, companies and hospitals.

Login With Facebook
MedicExchange Login

Enjoy Premium Access as a MedicExchange Member.

       Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Facebook Twitter Linkedin
Facebook: MedicExchange
Twitter: MedicExchange
Conferences Past Conferences SNM 2011 SNM 2011: Find out How to Meet the PET Deadline at SNM Meeting

SNM 2011: Find out How to Meet the PET Deadline at SNM Meeting

Medical Conferences News - SNM 2011


Visitors to the SNM 2011 Annual Meeting (San Antonio Texas June 4-8) can find out how LabLogic Systems’ PETra LIMS can ensure batch records for PET radiopharmaceuticals comply with new FDA regulations by the deadline at the end of this year.

From 12 December a PET radiopharmaceutical producer must maintain master production and control records - complete and detailed written documentation for each product covering methods used, QC tests performed and acceptance criteria.

For every product batch, the producer must maintain batch records, recording and documenting every production and QC process and comparing results of these processes and tests against the documented acceptance criteria for the product.  Any process deviations must also be recorded, and each batch record should include full details of the analyst, time and date for every procedure.

A producer should also maintain detailed standard operating procedures (SOPs) regarding each production or QC process so that they can be referred to in master production and control records.

Furthermore, there should be full traceability of all raw materials used in production, and documented controls to demonstrate that raw materials are of sufficient quality and maintained in adequate stock levels.

Lablogic’s PETra is a complete process management solution system that ensures compliance with these and the many other requirements for PET radiopharmaceutical producers set out in the forthcoming FDA CFR part 212 regulations and the amendments to USP 823.

Source: PRLog